One team constructing CD70 CAR-T for AML found that when AML exposure to AZA at physiologically dose-dependent concentrations increased the expression of CD70 antigen in tumor cells and enhanced the efficacy of CD70 CAR-T, then they demonstrated this in mice models [107]. The gene discussed is CD70; the disease is neoplasm.